
The withdrawal came on the eve of a Senate committee vote, leaving the FDA without a nominee as vaccine and mifepristone debates continue.
Chain execs attend the 70th Annual NACDS Meeting hoping to get answers to pressing questions facing pharmacy and their businesses.






